Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of ALN-PCSSC in Homozygous Familial Hypercholesterolemia
2016-003376-49Phase 2Completed
- Sponsor
- The Medicines Company
- Start
- Jan 2017
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inclisiran in homozygous familial hypercholesterolemia (HoFH), sponsored by The Medicines Company. Primary endpoint: Percentage change in LDL-C. Started Jan 2017; status: completed.
02
Drugs
inclisiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2016-003376-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003376-49.